uterine leiomyoma
Image Gallery
[ (||image_reduire{0,60}|inserer_attribut{alt,Uterine leiomyoma. Macroscopy.}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Uterine leiomyoma under the mucosa}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Uterine leiomyoma under the mucosa - tumor cut}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Multiple uterine leiomyomas}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Uterine leiomyomas.}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Submucosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Parietal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Parietal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Parietal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Myxoid degeneration of an uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Necrobiotic subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Necrobiotic subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Necrobiotic subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Necrobiotic subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Necrotic subserosal uterine leiomyoma}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Necrotic subserosal uterine leiomyoma}) ]
Uterine leiomyoma occurs in about 20-30% of women over the age of 30, and is the most frequent benign tumor in gynecology.
Cytogenetics
Cytogenetic analysis of uterine leiomyomata (UL) shows that about 40% of these benign tumors have simple, clonal chromosomal rearrangements.
near-diploid karyotypes with del(1)(p11p36) (#16320247#)
- often associated with other aberrations, particularly loss of chromosomes 19 (19-) and/or 22 (22-)
- cellular UL
- hypercellularity and nuclear atypia
1q42 rearrangement (FH, fumarate hydratase) (#15334541#, #12419594#)
10q22
- t(10;17) disrupts the histone acetyltransferase MORF (10q22) (monocytic leukemia zinc finger protein-related factor or MYST4). (#15313893#)
LOH and deletions
del(1)(p11p36) (#16320247#)
1q42 LOH and 1q42 deletions (FH, fumarate hydratase) (#15334541#, #12419594#)
7p15 LOH (#15605361#)
7p22
- 7q22 deletion
- 7q22 LOH (9%-34%) ((#15605361#, #10549262#, #9869453#)
7q LOH (9%) (#10484989#, #9869453#)
12q14 LOH (HMGA2)
15q26 LOH (#15605361#)
Molecular biology
allelotyping: #9869453#
transcriptional profiling: #15101043#
Variants
cellular uterine leiomyoma
References
Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, Mittal K, Soteropoulos P, Wei JJ. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer. 2007 Apr;46(4):336-47. PMID: #17243163#
Quade BJ, Wang TY, Sornberger K, Dal Cin P, Mutter GL, Morton CC. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer. 2004 Jun;40(2):97-108. PMID: #15101043#
Dal Cin P, Morton CC. 1q42 approximately q44 is rarely cytogenetically involved in sporadic uterine leiomyomata. Cancer Genet Cytogenet. 2002 Oct 1;138(1):92-3. PMID: #12419594#